tradingkey.logo

Vir Biotechnology Reports Positive Updated Phase 1 Results For Psma-Targeting, Pro-Xten Dual-Masked T-Cell Engager Vir-5500

ReutersFeb 23, 2026 10:26 PM

- Vir Biotechnology Inc VIR.O:

  • VIR BIOTECHNOLOGY REPORTS POSITIVE UPDATED PHASE 1 RESULTS FOR PSMA-TARGETING, PRO-XTEN® DUAL-MASKED T-CELL ENGAGER VIR-5500 IN PATIENTS WITH METASTATIC PROSTATE CANCER

  • VIR BIOTECHNOLOGY INC - VIR-5500 SHOWS FAVORABLE SAFETY PROFILE WITH NO DOSE-LIMITING TOXICITIES

  • VIR BIOTECHNOLOGY INC: ADVANCING DOSE-EXPANSION COHORTS AND PLAN TO INITIATE OUR REGISTRATIONAL TRIAL IN 2027

  • VIR BIOTECHNOLOGY INC - DOSE-DEPENDENT ANTI-TUMOR ACTIVITY OBSERVED WITH VIR-5500

  • VIR BIOTECHNOLOGY: 82% PSA50 & 53% PSA90 DECLINES & RECIST-EVALUABLE OBJECTIVE RESPONSES IN ≥3,000 ΜG/KG Q3W DOSING COHORTS WITH VIR-5500

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI